Dispatch Biotherapeutics
Latest round
- Series A
Last raised
- Jul 2025
Total raised
- $100M
Investors
- 6
About Dispatch Biotherapeutics
Dispatch Biotherapeutics, Inc.Founded in 2022, Dispatch Biotherapeutics specializes in providing innovative treatments for solid tumors. The company operates out of Philadelphia, US, and has executed 2 key deals since its inception.Dispatch Biotherapeutics specializes in developing innovative immunotherapy solutions aimed at treating solid tumors, an area where traditional cancer treatments have shown limited effectiveness. The core offering revolves around their Flare platform, designed to address the challenges of targeting and resistance commonly encountered in various solid tumor types. This first-in-class approach leverages advanced engineering methods to enhance the immune response against tumors, ultimately aiming for curative outcomes. The target market for these products includes healthcare providers and institutions involved in oncology, particularly in regions known for advanced cancer treatment infrastructure, such as North America and Europe.The revenue generation model for Dispatch Biotherapeutics is primarily based on partnerships and collaborations within the pharmaceutical and biotechnology sectors. Transactions typically occur through strategic alliances with healthcare institutions and research organizations, allowing for the distribution of their immunotherapy solutions. These partnerships may involve licensing agreements or shared development costs, facilitating access to their proprietary Flare platform. The company’s revenue is further supported by potential milestone payments and royalties linked to the successful commercialization of their products.Dispatch Biotherapeutics is focused on expanding its product portfolio and market reach. The company is actively working on new immunotherapy products aimed at providing innovative solutions for solid tumors. The firm intends to expand into European and Asian markets by 2025, targeting regions with robust oncology infrastructure. In July 2025, Dispatch Biotherapeutics, Inc.
Who invested in Dispatch Biotherapeutics
6 investors across 1 round
See all investors in Dispatch Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 9, 2025
Amount
$100M
Investors
Questions about Dispatch Biotherapeutics
Who invested in Dispatch Biotherapeutics?
Dispatch Biotherapeutics has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dispatch Biotherapeutics raised?
Dispatch Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Dispatch Biotherapeutics last raise money?
Dispatch Biotherapeutics's most recent round on record is a Series A, in Jul 2025.
What does Dispatch Biotherapeutics do?
Dispatch Biotherapeutics is a biotechnology company.
Where is Dispatch Biotherapeutics headquartered?
Dispatch Biotherapeutics is headquartered in Philadelphia, US.
Which VCs invest in companies like Dispatch Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Dispatch Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Dispatch Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.